FDA approves atezolizumab combinations for specified Stage III colon cancer — sources for revision 1
U.S. Food and Drug Administration
Source date: 2026-10-08.
Supporting location: Opening approval paragraphs; Efficacy and Safety.
Source dates are distinct from Iliyn’s preparation date. Source statements do not independently prove underlying events. No full source articles or source photographs are reproduced.